Edwards Lifesciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Marie Thibault from BTIG maintained a Buy rating on the stock and has a $100.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marie Thibault’s rating is based on the promising results from the seven-year data of Edwards Lifesciences’ PARTNER 3 study, which were presented at the Transcatheter Cardiovascular Therapeutics annual meeting. The study compared outcomes between the Sapien 3 transcatheter aortic valve replacement (TAVR) and traditional surgery in patients with severe aortic stenosis who are at low surgical risk. The data showed similar rates of clinical events between the two groups, with the Sapien 3 group demonstrating a slightly lower event rate for the primary endpoint compared to the surgery group.
Importantly, the study highlighted that the differences in death rates, both cardiovascular and non-cardiovascular, were not statistically significant between the two groups. Additionally, the valve hemodynamics and durability were comparable, with similar mean aortic-valve gradients and bioprosthetic valve failure rates. These findings suggest that the Sapien 3 valve remains a viable alternative to surgery, particularly for younger, low-risk patients. As a result, Marie Thibault maintains a positive outlook on Edwards Lifesciences, reinforcing her Buy rating.
Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of EW in relation to earlier this year.